Athira Pharma Statistics
Share Statistics
Athira Pharma has 38.67M shares outstanding. The number of shares has increased by 0.89% in one year.
| Shares Outstanding | 38.67M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 35.36M |
| Failed to Deliver (FTD) Shares | 1.40K |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 1.56M, so 4.03% of the outstanding shares have been sold short.
| Short Interest | 1.56M |
| Short % of Shares Out | 4.03% |
| Short % of Float | 4.38% |
| Short Ratio (days to cover) | 2.74 |
Valuation Ratios
The PE ratio is -0.79 and the forward PE ratio is -0.49.
| PE Ratio | -0.79 |
| Forward PE | -0.49 |
| PS Ratio | 0 |
| Forward PS | 1.5 |
| PB Ratio | 0.71 |
| P/FCF Ratio | -0.91 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Athira Pharma Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.37, with a Debt / Equity ratio of 0.
| Current Ratio | 5.37 |
| Quick Ratio | 5.37 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.9% and return on capital (ROIC) is -95.21%.
| Return on Equity (ROE) | -0.9% |
| Return on Assets (ROA) | -0.73% |
| Return on Capital (ROIC) | -95.21% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.81M |
| Employee Count | 65 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -83.23% in the last 52 weeks. The beta is 2.83, so Athira Pharma 's price volatility has been higher than the market average.
| Beta | 2.83 |
| 52-Week Price Change | -83.23% |
| 50-Day Moving Average | 0.61 |
| 200-Day Moving Average | 1.71 |
| Relative Strength Index (RSI) | 41.69 |
| Average Volume (20 Days) | 4.89M |
Income Statement
| Revenue | n/a |
| Gross Profit | -969.00K |
| Operating Income | -125.47M |
| Net Income | -117.67M |
| EBITDA | -116.70M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.1 |
Balance Sheet
The company has 90.58M in cash and 1.58M in debt, giving a net cash position of 89.00M.
| Cash & Cash Equivalents | 90.58M |
| Total Debt | 1.58M |
| Net Cash | 89.00M |
| Retained Earnings | -309.21M |
| Total Assets | 86.25M |
| Working Capital | 54.25M |
Cash Flow
In the last 12 months, operating cash flow was -100.75M and capital expenditures -304.00K, giving a free cash flow of -101.06M.
| Operating Cash Flow | -100.75M |
| Capital Expenditures | -304.00K |
| Free Cash Flow | -101.06M |
| FCF Per Share | -2.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ATHA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -584.91% |
| FCF Yield | -490.78% |
Analyst Forecast
The average price target for ATHA is $11.25, which is 2022.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $11.25 |
| Price Target Difference | 2022.6% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -9.39 |
| Piotroski F-Score | 2 |